HC Wainwright Boosts Cybin (NASDAQ:HELP) Price Target to $95.00

Cybin (NASDAQ:HELP) had its target price lifted by stock analysts at HC Wainwright from $55.00 to $95.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Separately, Jefferies Financial Group began coverage on Cybin in a report on Monday, February 2nd. They set a “buy” rating and a $22.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $58.50.

Cybin Trading Up 3.8%

Shares of HELP stock opened at $7.90 on Monday. Cybin has a 52-week low of $4.81 and a 52-week high of $9.83. The stock has a market capitalization of $395.32 million, a PE ratio of -1.87 and a beta of 0.61.

Cybin (NASDAQ:HELP) last posted its quarterly earnings results on Friday, February 13th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.19).

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.